Treatment of Intraocular Retinoblastoma

Retinoblastoma Clinical Trial

Official title: Clinical Study of Superselective Ophthalmic Artery Interventional Chemotherapy for Intraocular Retinoblastoma

Status Not yet recruiting

Clinical Trial Summary

This study compares the effects of balloon technology and microcatheter technology on the eye protection rate of neuroblastoma

Clinical Trial Description

Retinoblastoma is the most common intraocular malignant tumor in childhood, with an incidence of about 1/15,000-20,000, accounting for 4% of all childhood cancers. All patients with bilateral reticuloblastoma and approximately 10%-15% of children with unilateral disease have germline mutations that can be passed on to their offspring.In developed countries, the survival rate is close to 98%. However, due to the limitations of health care in low-income countries, this proportion is much lower, about 40%. Before the 1990s, retinoblastoma was mainly treated with enucleation and external beam radiation therapy (EBRT). However, these methods are associated with many complications, including vision loss and serious side effects. At present, the first-line conservative treatment of retinoblastoma has changed from EBRT and enucleation to Intravenous chemotherapy (IVC) or intra-arterial chemotherapy (IAC), and it has been consolidated through focal treatment. There are two different surgical procedures for intra-arterial chemotherapy, namely balloon technique and microcatheter technique. Investigators observe their effects through a retrospective case-control study. ;

Related Conditions & MeSH terms

• Retinoblastoma

• NCT number: NCT05028270
• Study type: Observational
• Source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Chaohui Jin, Phd, MD
• Phone: +8613636694571
• Email: 13636694571@163.com
• Status: Not yet recruiting
• Start date: June 20, 2022
• Completion date: August 1, 2023